🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ZIM Laboratories Limited ZIMLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.zimlab.in
Company Profile ↓
₹115.89
+0.84% 1Y
Mkt Cap₹620.02 Cr
P/E46.36
P/B2.09
52W High₹127.87
52W Low₹60.26
Book Value₹55.36
EPS (TTM)₹2.50

Company Overview

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was founded in 1984 and is based in Nagpur, India.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹360.04 Cr (-0.8% YoY); net profit ₹5.84 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -0.8%, earnings -52.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -2.5%, profit CAGR -37.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-2.52%
1 Year:-0.78%

Compounded Profit Growth

5 Years:-37.95%
1 Year:-52.01%

Stock Price Performance

1 Year:+0.84%
6 Months:+65.44%
3 Months:+59.34%
1 Month:+1.31%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 82% of range
₹60.26 ₹127.87
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)49.79 · Neutral
Price Performance
1M+1.31%
3M+59.34%
6M+65.44%
1Y+0.84%
Valuation vs Sector

P/E of 46.36 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -2.5% CAGR over 5 years.
  • Earnings shrank at -37.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
46.36
Industry PE
39.97
Forward P/E est.
92.72
PEG Ratio
-
Book Value
₹55.36
Price to Book
2.09
P/S
1.66
EV/EBITDA
27.95
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-2.52%
Profit 5Y
-37.95%
Revenue (YoY)
-0.78%
Earnings (YoY)
-52.01%

Profitability & Returns

ROCE
5.81%
ROE
1.97%
ROA
1.08%
Profit Margin
1.62%
Op Margin
3.08%
Gross Margin
53.80%
EPS (Latest Qtr)
₹0.76
EPS (TTM)
₹2.50

Balance Sheet & Liquidity

Debt/Equity
0.43
Quick Ratio
0.96
Current Ratio
1.45
Debt
₹126.40 Cr
Total Assets
₹539.39 Cr
Current Assets
₹275.81 Cr
Working Capital
₹85.42 Cr

Ownership

Promoter Holding
71.35%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-0.07%

Financial Snapshot

Enterprise Value
₹620.02 Cr
Total Revenue (TTM)
₹360.04 Cr
EBITDA
₹40.27 Cr
Free Cash Flow
₹5.15 Cr
Operating Cash Flow
₹49.53 Cr
Shares Outstanding
₹5.35 Cr
Gross Margin
53.80%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ZIMLAB ZIM Laboratories Limited NSEPHARMA 115.89 46.36 ₹620.02 Cr 0.00% 5.81% 1.97% -2.52% -37.95%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 105.41 Cr67.44 Cr85.83 Cr96.29 Cr117.86 Cr81.82 Cr92.14 Cr96.33 Cr108.73 Cr71.76 Cr88.71 Cr108.66 Cr105.27 Cr
Cost of Revenue --------48.26 Cr30.01 Cr39.64 Cr48.60 Cr47.12 Cr
Gross Profit --------60.48 Cr41.75 Cr49.07 Cr60.06 Cr58.15 Cr
Operating Expenses 89.96 Cr62.62 Cr76.50 Cr84.75 Cr102.21 Cr73.78 Cr82.61 Cr84.77 Cr51.17 Cr42.35 Cr48.29 Cr52.29 Cr56.06 Cr
Operating Income 10.52 Cr79.00 L5.24 Cr7.60 Cr11.74 Cr3.10 Cr4.53 Cr6.68 Cr9.31 Cr-60.48 L77.26 L7.77 Cr2.09 Cr
EBITDA 15.45 Cr4.82 Cr9.33 Cr11.54 Cr15.65 Cr8.04 Cr9.53 Cr11.56 Cr16.31 Cr5.74 Cr7.80 Cr14.51 Cr13.35 Cr
Interest Expense 1.27 Cr1.73 Cr1.22 Cr1.70 Cr2.28 Cr2.86 Cr2.89 Cr2.73 Cr2.91 Cr3.30 Cr3.16 Cr3.43 Cr3.31 Cr
Pretax Income 9.94 Cr18.00 L5.44 Cr7.01 Cr10.99 Cr1.24 Cr2.96 Cr5.70 Cr8.11 Cr-2.43 Cr-34.38 L6.05 Cr4.94 Cr
Tax Provision 2.70 Cr-4.00 L1.29 Cr2.23 Cr2.91 Cr34.00 L57.99 L1.71 Cr3.22 Cr-55.71 L8.08 L1.65 Cr1.20 Cr
Net Income 7.24 Cr23.00 L4.15 Cr4.78 Cr8.09 Cr90.00 L2.38 Cr4.00 Cr4.88 Cr-1.87 Cr-42.46 L4.40 Cr3.74 Cr
Diluted EPS 1.490.050.850.981.660.180.490.821.01-0.38-0.090.900.76

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 266.00 Cr269.00 Cr235.00 Cr273.00 Cr335.00 Cr278.00 Cr307.00 Cr-388.73 Cr355.51 Cr362.89 Cr360.04 Cr
Cost of Revenue --------199.94 Cr172.37 Cr168.74 Cr166.35 Cr
Gross Profit --------188.79 Cr183.14 Cr194.15 Cr193.69 Cr
Operating Expenses 278.00 Cr239.00 Cr203.00 Cr238.00 Cr293.00 Cr255.00 Cr268.00 Cr-153.53 Cr156.37 Cr167.55 Cr182.61 Cr
Operating Income -19.00 Cr21.00 Cr23.00 Cr25.00 Cr31.00 Cr9.00 Cr24.00 Cr-35.26 Cr26.77 Cr26.60 Cr11.08 Cr
EBITDA -12.00 Cr30.00 Cr32.00 Cr35.00 Cr42.00 Cr23.00 Cr40.00 Cr-57.79 Cr45.48 Cr48.37 Cr40.27 Cr
Interest Expense 10.00 Cr14.00 Cr10.00 Cr9.00 Cr11.00 Cr13.00 Cr11.00 Cr-4.97 Cr5.88 Cr10.25 Cr12.08 Cr
Pretax Income -27.00 Cr5.00 Cr18.00 Cr25.00 Cr22.00 Cr010.00 Cr-35.35 Cr23.64 Cr18.01 Cr8.21 Cr
Tax Provision 5.13 Cr25.00 L-1.08 Cr5.75 Cr6.60 Cr-02.80 Cr-10.92 Cr6.40 Cr5.84 Cr2.37 Cr
Net Income -22.00 Cr5.00 Cr19.00 Cr19.00 Cr15.00 Cr3.00 Cr7.00 Cr-24.43 Cr17.25 Cr12.17 Cr5.84 Cr
Diluted EPS ----3.170.681.502.995.013.542.50-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 265.00 Cr256.00 Cr259.00 Cr298.00 Cr328.00 Cr325.00 Cr325.00 Cr-341.58 Cr446.82 Cr472.27 Cr539.39 Cr
Current Assets --------190.95 Cr227.65 Cr231.31 Cr275.81 Cr
Cash & Equivalents --------6.42 Cr9.60 Cr1.95 Cr25.12 Cr
Inventory --------53.71 Cr81.26 Cr86.47 Cr93.77 Cr
Receivables --------95.25 Cr100.17 Cr106.92 Cr109.04 Cr
Total Liabilities --------141.23 Cr208.08 Cr220.04 Cr243.23 Cr
Current Liabilities --------110.79 Cr159.43 Cr166.36 Cr190.39 Cr
Long Term Debt --------24.62 Cr35.60 Cr40.30 Cr41.59 Cr
Total Debt 93.00 Cr96.00 Cr81.00 Cr81.00 Cr77.00 Cr90.00 Cr82.00 Cr-62.00 Cr111.63 Cr117.68 Cr126.40 Cr
Total Equity 94.00 Cr99.00 Cr118.00 Cr137.00 Cr151.00 Cr154.00 Cr161.00 Cr-200.35 Cr238.75 Cr252.24 Cr296.15 Cr
Shares Outstanding --------4.87 Cr4.87 Cr4.87 Cr5.35 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -22.00 Cr32.00 Cr37.00 Cr35.00 Cr22.00 Cr32.00 Cr-38.17 Cr16.28 Cr41.15 Cr49.53 Cr
Investing Cash Flow --12.00 Cr-7.00 Cr-26.00 Cr-21.00 Cr-19.00 Cr-6.00 Cr--36.20 Cr-73.01 Cr-39.93 Cr-56.35 Cr
Financing Cash Flow --10.00 Cr-25.00 Cr-10.00 Cr-15.00 Cr-2.00 Cr-26.00 Cr-54.56 L59.53 Cr-9.10 Cr28.19 Cr
Capital Expenditure --13.00 Cr-8.00 Cr-29.00 Cr-20.00 Cr-19.00 Cr-7.00 Cr--36.67 Cr-73.92 Cr-40.80 Cr-44.39 Cr
Free Cash Flow -9.00 Cr24.00 Cr8.00 Cr15.00 Cr3.00 Cr25.00 Cr-1.50 Cr-57.65 Cr35.69 L5.15 Cr
Net Change in Cash --0-01.00 Cr-1.00 Cr1.00 Cr-0-2.51 Cr2.80 Cr-7.88 Cr21.37 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------48.6%51.5%53.5%53.8%
Operating Margin % -7.1%7.8%9.8%9.2%9.3%3.2%7.8%-9.1%7.5%7.3%3.1%
Net Margin % -8.3%1.9%8.1%7.0%4.5%1.1%2.3%-6.3%4.9%3.4%1.6%
ROE % -23.4%5.1%16.1%13.9%9.9%1.9%4.3%-12.2%7.2%4.8%2.0%
ROCE % --------15.3%9.3%8.7%3.2%

Shareholding Pattern

Insiders
71.35%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ZIMLAB

Google News hu, 22 Dec 2022

ZIMLAB Stock Price and Chart — NSE:ZIMLAB - TradingView

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTFByLWY3c20tZi1aUUN4QzBMUDlkUmJRc2h3UldEQTVOaFBESUR2TlJJZEFrd3NqZmszaE9RMTZCRHdSaU9kdzRDdmtwVXJkN1hjOFF5NVllTlM1VW8?oc=5" target="_blank">ZIMLAB Stock Price and Chart — NSE:ZIMLAB</a…

Google News hu, 03 Jul 2025

ZIM Laboratories Limited's (NSE:ZIMLAB) 26% Price Boost Is Out Of Tune With Earnings - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOV1BvelZNdlpPVndiQzctTU1HclBwVVZNTkQyT25FRkFiNkFIVlZpNmlrbUxQT2VuUDlSTi1STHEzMm9QMVZkbmFXbzRfdnZFb01BOFhQT3ViX2N1bkZWMXJueUFEWkdHdkFKQUVDN0V0YVZPNXJ4eTVOSGdhN2Q3MVNkbVZDMk9rUlJmQm…

Google News Wed, 20 May 2026

ZIM Lab Standalone March 2026 Net Sales at Rs 102.85 crore, down 5.22% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOT1VSOTF4Um91dmk4ZzJ2ZmF0aTVGLWh0R1JUSGEySFRGQVZPRDRkM1BEaUFyaE9wR25jUlk5RlBBZWoxV09OdTdMMC12cnJlLUhONFRpS28xcTB3cWhkYzJwVlZfbzhlREl3OTlFblo4V1RNMzRsbEFTdEh2Y0hHUlFJN0EwbTRscHBXVl…

Google News Fri, 13 Oct 2017

JAGSNPHARM Stock Price and Chart — NSE:JAGSNPHARM - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9DR0tucW5fck9oU2lWZTNsZWVMUTQxdE5OZDAxZGpwS29TeFhqRjNCbTlPUHBzb3cxMWZpR3pleDRnZEpkZGRHYVRrNUd3ZFY3WEsxQlR0N1ZZc3BTWkxvSA?oc=5" target="_blank">JAGSNPHARM Stock Price and Chart — NS…

ZIMLAB — Frequently Asked Questions

What is the current share price of ZIM Laboratories Limited (ZIMLAB)?

As of 2026-07-15 09:52 IST, ZIM Laboratories Limited (ZIMLAB) trades at ₹115.89 on NSE. Its 52-week range is ₹60.26 to ₹127.87.

What is the market capitalisation of ZIMLAB?

ZIM Laboratories Limited (ZIMLAB) has a market capitalisation of ₹620.02 Cr on NSE.

What is the P/E ratio of ZIMLAB?

ZIMLAB trades at a trailing price-to-earnings (P/E) ratio of 46.36. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.09.

What is the return on equity (ROE) of ZIMLAB?

ZIMLAB has a return on equity (ROE) of 1.97%. Its return on capital employed (ROCE) is 5.81%.

Is ZIMLAB a good stock to buy?

This page provides a data-driven analysis of ZIM Laboratories Limited (ZIMLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space